You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSotalol
Accession NumberDB00489  (APRD01230)
TypeSmall Molecule
GroupsApproved
DescriptionAn adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias. [PubChem]
Structure
Thumb
Synonyms
4'-(1-Hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide
beta-Cardone
Sotalol
Sotalolo
Sotalolum
External Identifiers
  • MJ 1999
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-sotalolTablet80 mgOralAvanstra Inc2011-08-112014-08-21Canada
Ava-sotalolTablet160 mgOralAvanstra Inc2011-08-112014-08-21Canada
BetapaceTablet80 mg/1OralBayer Health Care Pharmaceuticals Inc.1992-10-30Not applicableUs
BetapaceTablet120 mg/1OralCovis Pharma2016-09-01Not applicableUs
BetapaceTablet160 mg/1OralBayer Health Care Pharmaceuticals Inc.1992-10-30Not applicableUs
BetapaceTablet120 mg/1OralBayer Health Care Pharmaceuticals Inc.1992-10-30Not applicableUs
BetapaceTablet80 mg/1OralCovis Pharma2016-09-01Not applicableUs
BetapaceTablet160 mg/1OralCovis Pharma2016-09-01Not applicableUs
Betapace AFTablet120 mg/1OralCovis Pharma2016-09-01Not applicableUs
Betapace AFTablet160 mg/1OralBayer Health Care Pharmaceuticals Inc.2000-02-22Not applicableUs
Betapace AFTablet80 mg/1OralCovis Pharma2016-09-01Not applicableUs
Betapace AFTablet120 mg/1OralBayer Health Care Pharmaceuticals Inc.2000-02-22Not applicableUs
Betapace AFTablet160 mg/1OralCovis Pharma2016-09-01Not applicableUs
Betapace AFTablet80 mg/1OralBayer Health Care Pharmaceuticals Inc.2000-02-22Not applicableUs
Co SotalolTablet80 mgOralCobalt Pharmaceuticals Company2006-07-13Not applicableCanada
Co SotalolTablet160 mgOralCobalt Pharmaceuticals Company2006-07-13Not applicableCanada
Dom-sotalolTablet160 mgOralDominion Pharmacal1998-09-17Not applicableCanada
Dom-sotalolTablet80 mgOralDominion Pharmacal1998-09-17Not applicableCanada
Ftp-sotalolTablet160 mgOralFtp Pharmacal Inc.1998-10-092004-08-03Canada
Ftp-sotalolTablet80 mgOralFtp Pharmacal Inc.1998-10-092004-08-03Canada
Gen-sotalol 240mgTablet240 mgOralGenpharm Ulc1996-10-212009-08-05Canada
Jamp-sotalolTablet160 mgOralJamp Pharma Corporation2011-10-20Not applicableCanada
Jamp-sotalolTablet80 mgOralJamp Pharma Corporation2011-10-20Not applicableCanada
Linsotalol - Tab 80mgTablet80 mgOralLinson Pharma Co.1995-12-312006-05-29Canada
Linsotalol -tab 160mgTablet160 mgOralLinson Pharma Co.1995-12-312006-05-29Canada
Med SotalolTablet80 mgOralMedican Pharma Incorporated1998-02-052011-03-29Canada
Med SotalolTablet160 mgOralMedican Pharma Incorporated1998-02-052011-03-29Canada
Mylan-sotalolTablet160 mgOralMylan Pharmaceuticals Ulc1996-10-21Not applicableCanada
Mylan-sotalolTablet80 mgOralMylan Pharmaceuticals Ulc1996-10-21Not applicableCanada
Novo-sotalol Tab 160mgTablet160 mgOralNovopharm Limited1997-05-132015-10-26Canada
Novo-sotalol Tab 80mgTablet80 mgOralNovopharm Limited1997-05-132015-10-26Canada
Nu-sotalol - Tab 160 mgTablet160 mgOralNu Pharm Inc1995-12-312012-09-04Canada
Nu-sotalol - Tab 80mgTablet80 mgOralNu Pharm Inc1996-12-312012-09-04Canada
PHL-sotalolTablet80 mgOralPharmel Inc1998-12-01Not applicableCanada
PHL-sotalolTablet160 mgOralPharmel Inc1998-12-01Not applicableCanada
PMS-sotalol - 160 mgTablet160 mgOralPharmascience Inc1998-07-22Not applicableCanada
PMS-sotalol - 240 mgTablet240 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-sotalol - 80 mgTablet80 mgOralPharmascience Inc1998-07-22Not applicableCanada
Pro-sotalolTablet80 mgOralPro Doc Limitee2008-10-15Not applicableCanada
Pro-sotalolTablet160 mgOralPro Doc Limitee2008-10-15Not applicableCanada
Ratio-sotalolTablet80 mgOralTeva Canada Limited1995-12-31Not applicableCanada
Ratio-sotalolTablet160 mgOralTeva Canada Limited1995-12-31Not applicableCanada
Rho-sotalolTablet240 mgOralRhoxalpharma IncNot applicableNot applicableCanada
Rhoxal-sotalolTablet80 mgOralRhoxalpharma Inc1997-12-022009-11-24Canada
Rhoxal-sotalolTablet160 mgOralRhoxalpharma Inc1997-12-022009-11-24Canada
Riva-sotalolTablet80 mgOralLaboratoire Riva Inc2010-06-04Not applicableCanada
Riva-sotalolTablet160 mgOralLaboratoire Riva Inc2000-05-232016-07-15Canada
Riva-sotalolTablet80 mgOralLaboratoire Riva Inc2000-05-232013-07-31Canada
Riva-sotalolTablet160 mgOralLaboratoire Riva Inc2016-07-15Not applicableCanada
RylosolTablet80 mgOralValeant Canada Lp Valeant Canada S.E.C.1997-05-272014-07-30Canada
RylosolTablet160 mgOralValeant Canada Lp Valeant Canada S.E.C.1997-05-272014-07-30Canada
RylosolTablet240 mgOralValeant Canada Lp Valeant Canada S.E.C.1997-05-272014-07-30Canada
Sandoz SotalolTablet160 mgOralSandoz Canada Incorporated2004-09-21Not applicableCanada
Sandoz SotalolTablet80 mgOralSandoz Canada Incorporated2004-09-21Not applicableCanada
Sotacor Tab 160mgTablet160 mgOralBristol Labs Division Of Bristol Myers Squibb1985-12-312005-08-01Canada
Sotacor Tab 240mgTablet240 mgOralBristol Labs Division Of Bristol Myers Squibb1993-12-311996-09-09Canada
Sotacor Tab 80mgTablet80 mgOralBristol Labs Division Of Bristol Myers Squibb1993-12-312005-08-01Canada
SotalolTablet160 mgOralSorres Pharma Inc2009-06-222014-06-20Canada
SotalolTablet80 mgOralSivem Pharmaceuticals Ulc2012-06-11Not applicableCanada
SotalolTablet160 mgOralSivem Pharmaceuticals Ulc2012-06-11Not applicableCanada
SotalolTablet80 mgOralSorres Pharma Inc2009-06-222014-06-20Canada
Sotalol HydrochlorideInjection15 mg/mLIntravenousAltathera Pharmaceuticals, Llc2015-10-15Not applicableUs
Sotalol HydrochlorideInjection15 mg/mLIntravenousMylan Institutional LLC2009-09-30Not applicableUs
Sotalol-160 - Tab 160mgTablet160 mgOralPro Doc Limitee1997-01-152009-07-23Canada
Sotalol-80 - Tab 80mgTablet80 mgOralPro Doc Limitee1997-01-152010-07-13Canada
SotamolTablet160 mgOralTechnilab Pharma Inc.1998-10-292006-07-28Canada
SotamolTablet80 mgOralTechnilab Pharma Inc.1998-10-292006-07-28Canada
SotylizeSolution5 mg/mLOralArbor Pharmaceuticals, Inc.2015-03-01Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-sotalol - Tab 160mgTablet160 mgOralApotex Inc1995-12-31Not applicableCanada
Apo-sotalol 80mg TabletsTablet80 mgOralApotex Inc1996-12-31Not applicableCanada
SorineTablet240 mg/1OralUpsher Smith Laboratories, Inc.2011-02-15Not applicableUs
SorineTablet80 mg/1OralUpsher Smith Laboratories, Inc.2011-02-15Not applicableUs
SorineTablet120 mg/1OralUpsher Smith Laboratories, Inc.2011-02-15Not applicableUs
SorineTablet160 mg/1OralUpsher Smith Laboratories, Inc.2011-02-15Not applicableUs
SorineTablet80 mg/1OralCardinal Health2011-02-15Not applicableUs
Sotalol HydrochlorideTablet240 mg/1OralGlobal Pharmaceuticals2000-11-072016-11-29Us
Sotalol HydrochlorideTablet80 mg/1OralEpic Pharma, LLC2016-01-04Not applicableUs
Sotalol HydrochlorideTablet80 mg/1OralLake Erie Medical DBA Quality Care Products LLC2003-11-07Not applicableUs
Sotalol HydrochlorideTablet160 mg/1OralGolden State Medical Supply, Inc.2003-02-01Not applicableUs
Sotalol HydrochlorideTablet160 mg/1OralPhysicians Total Care, Inc.2006-03-14Not applicableUs
Sotalol HydrochlorideTablet120 mg/1OralTeva Pharmaceuticals USA Inc2000-05-05Not applicableUs
Sotalol HydrochlorideTablet160 mg/1OralApotex Corp.2003-09-09Not applicableUs
Sotalol HydrochlorideTablet80 mg/1OralAmerican Health Packaging2014-03-18Not applicableUs
Sotalol HydrochlorideTablet120 mg/1OralQualitest Pharmaceuticals2003-11-07Not applicableUs
Sotalol HydrochlorideTablet160 mg/1OralAv Kare, Inc.2014-02-13Not applicableUs
Sotalol HydrochlorideTablet240 mg/1OralApotex Corp.2003-02-01Not applicableUs
Sotalol HydrochlorideTablet160 mg/1OralEon Labs, Inc.2000-05-01Not applicableUs
Sotalol HydrochlorideTablet80 mg/1OralAmerican Health Packaging2013-06-122016-01-01Us
Sotalol HydrochlorideTablet80 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-11-07Not applicableUs
Sotalol HydrochlorideTablet160 mg/1OralGolden State Medical Supply, Inc.2003-09-09Not applicableUs
Sotalol HydrochlorideTablet80 mg/1OralGlobal Pharmaceuticals2000-11-072016-11-29Us
Sotalol HydrochlorideTablet160 mg/1OralLake Erie Medical DBA Quality Care Products LLC2003-11-07Not applicableUs
Sotalol HydrochlorideTablet240 mg/1OralGolden State Medical Supply, Inc.2003-02-01Not applicableUs
Sotalol HydrochlorideTablet120 mg/1OralEon Labs, Inc.2000-05-01Not applicableUs
Sotalol HydrochlorideTablet120 mg/1OralEpic Pharma, LLC2016-01-04Not applicableUs
Sotalol HydrochlorideTablet80 mg/1OralMylan Pharmaceuticals Inc.2007-02-20Not applicableUs
Sotalol HydrochlorideTablet120 mg/1OralPhysicians Total Care, Inc.2009-04-08Not applicableUs
Sotalol HydrochlorideTablet80 mg/1OralTeva Pharmaceuticals USA Inc2000-05-04Not applicableUs
Sotalol HydrochlorideTablet80 mg/1OralProficient Rx LP2003-11-07Not applicableUs
Sotalol HydrochlorideTablet80 mg/1OralCarilion Materials Management2003-11-07Not applicableUs
Sotalol HydrochlorideTablet160 mg/1OralQualitest Pharmaceuticals2003-11-07Not applicableUs
Sotalol HydrochlorideTablet80 mg/1OralPd Rx Pharmaceuticals, Inc.2000-05-01Not applicableUs
Sotalol HydrochlorideTablet120 mg/1OralApotex Corp.2003-02-01Not applicableUs
Sotalol HydrochlorideTablet80 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-02-01Not applicableUs
Sotalol HydrochlorideTablet80 mg/1OralGolden State Medical Supply, Inc.2003-02-01Not applicableUs
Sotalol HydrochlorideTablet120 mg/1OralGlobal Pharmaceuticals2000-11-072016-11-29Us
Sotalol HydrochlorideTablet80 mg/1OralAv Kare, Inc.2014-02-13Not applicableUs
Sotalol HydrochlorideTablet80 mg/1OralApotex Corp.2003-02-01Not applicableUs
Sotalol HydrochlorideTablet80 mg/1OralEon Labs, Inc.2000-05-01Not applicableUs
Sotalol HydrochlorideTablet160 mg/1OralEpic Pharma, LLC2016-01-04Not applicableUs
Sotalol HydrochlorideTablet120 mg/1OralMylan Pharmaceuticals Inc.2007-02-20Not applicableUs
Sotalol HydrochlorideTablet80 mg/1OralGolden State Medical Supply, Inc.2003-09-09Not applicableUs
Sotalol HydrochlorideTablet160 mg/1OralTeva Pharmaceuticals USA Inc2000-05-05Not applicableUs
Sotalol HydrochlorideTablet80 mg/1Oralbryant ranch prepack2003-11-07Not applicableUs
Sotalol HydrochlorideTablet80 mg/1OralA S Medication Solutions2003-02-01Not applicableUs
Sotalol HydrochlorideTablet240 mg/1OralQualitest Pharmaceuticals2003-11-07Not applicableUs
Sotalol HydrochlorideTablet80 mg/1OralAidarex Pharmaceuticals LLC2003-02-01Not applicableUs
Sotalol HydrochlorideTablet80 mg/1OralApotex Corp.2003-09-09Not applicableUs
Sotalol HydrochlorideTablet160 mg/1OralGlobal Pharmaceuticals2000-11-072016-11-29Us
Sotalol HydrochlorideTablet80 mg/1OralRebel Distributors Corp2000-05-01Not applicableUs
Sotalol HydrochlorideTablet120 mg/1OralGolden State Medical Supply, Inc.2003-02-01Not applicableUs
Sotalol HydrochlorideTablet120 mg/1OralAv Kare, Inc.2014-02-13Not applicableUs
Sotalol HydrochlorideTablet160 mg/1OralApotex Corp.2003-02-01Not applicableUs
Sotalol HydrochlorideTablet240 mg/1OralEon Labs, Inc.2000-05-01Not applicableUs
Sotalol HydrochlorideTablet80 mg/1OralQualitest Pharmaceuticals2003-11-07Not applicableUs
Sotalol HydrochlorideTablet80 mg/1OralA S Medication Solutions2003-11-07Not applicableUs
Sotalol HydrochlorideTablet160 mg/1OralMylan Pharmaceuticals Inc.2007-02-20Not applicableUs
Sotalol HydrochlorideTablet120 mg/1OralGolden State Medical Supply, Inc.2003-09-09Not applicableUs
Sotalol HydrochlorideTablet240 mg/1OralTeva Pharmaceuticals USA Inc2000-05-05Not applicableUs
Sotalol HydrochlorideTablet80 mg/1Oralbryant ranch prepack2003-11-07Not applicableUs
Sotalol HydrochlorideTablet80 mg/1OralPhysicians Total Care, Inc.2000-12-04Not applicableUs
Sotalol HydrochlorideTablet120 mg/1OralApotex Corp.2003-09-09Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BiosotalSanofi-Aventis
CardolAlphapharm
DarobAbbott
Darob miteAbbott
HipecorMerck
LoritmikKrka
RytmobetaAbbott
SotacorBristol-Myers Squibb
SotagardGlaxoSmithKline
SotalexBristol-Myers Squibb
SotaporBristol-Myers Squibb
TalozinAdeka
Tan ShiChia Tai Tianqing
Xi An LinChangzhou Pharmaceutical Factory
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Sotalol Hydrochloride
959-24-0
Thumb
  • InChI Key: VIDRYROWYFWGSY-UHFFFAOYNA-N
  • Monoisotopic Mass: 308.096140945
  • Average Mass: 308.825
DBSALT000318
Categories
UNIIA6D97U294I
CAS number3930-20-9
WeightAverage: 272.364
Monoisotopic: 272.119463206
Chemical FormulaC12H20N2O3S
InChI KeyZBMZVLHSJCTVON-UHFFFAOYSA-N
InChI
InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3
IUPAC Name
N-(4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}phenyl)methanesulfonamide
SMILES
CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1
Pharmacology
IndicationFor the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm. Also for the treatment of documented life-threatening ventricular arrhythmias.
Structured Indications
PharmacodynamicsSotalol is an antiarrhythmic drug. It falls into the class of beta blockers (and class II antiarrhythmic agents) because of its primary action on the β-adrenergic receptors in the heart. In addition to its actions on the beta receptors in the heart, sotalol inhibits the inward potassium ion channels of the heart. In so doing, sotalol prolongs repolarization, therefore lengthening the QT interval and decreasing automaticity. It also slows atrioventricular (AV) nodal conduction. Because of these actions on the cardiac action potential, it is also considered a class III antiarrhythmic agent. The beta-blocking effect of sotalol is non-cardioselective, half maximal at about 80mg/day and maximal at doses between 320 and 640 mg/day. Sotalol does not have partial agonist or membrane stabilizing activity. Although significant beta-blockade occurs at oral doses as low as 25 mg, significant Class Ieffects are seen only at daily doses of 160 mg and above.
Mechanism of actionSotalol has both beta-adrenoreceptor blocking (Vaughan Williams Class I) and cardiac action potential duration prolongation (Vaughan Williams Class I) antiarrhythmic properties. Sotalol is a racemic mixture of d- and l-sotalol. Both isomers have similar Class I antiarrhythmic effects, while the l-isomer is responsible for virtually all of the beta-blocking activity. Sotalol inhibits response to adrenergic stimuli by competitively blocking β1-adrenergic receptors within the myocardium and β2-adrenergic receptors within bronchial and vascular smooth muscle. The electrophysiologic effects of sotalol may be due to its selective inhibition of the rapidly activating component of the potassium channel involved in the repolarization of cardiac cells. The class II electrophysiologic effects are caused by an increase in sinus cycle length (slowed heart rate), decreased AV nodal conduction, and increased AV nodal refractoriness, while the class III electrophysiological effects include prolongation of the atrial and ventricular monophasic action potentials, and effective refractory period prolongation of atrial muscle, ventricular muscle, and atrio-ventricular accessory pathways (where present) in both the anterograde and retrograde directions.
TargetKindPharmacological actionActionsOrganismUniProt ID
Potassium voltage-gated channel subfamily H member 2Proteinyes
inhibitor
HumanQ12809 details
Beta-1 adrenergic receptorProteinyes
antagonist
HumanP08588 details
Beta-2 adrenergic receptorProteinyes
antagonist
HumanP07550 details
Related Articles
AbsorptionIn healthy subjects, the oral bioavailability of sotalol is 90-100%. Absorption is reduced by approximately 20% compared to fasting when administered with a standard meal.
Volume of distributionNot Available
Protein bindingSotalol does not bind to plasma proteins.
Metabolism

Sotalol is not metabolized.

Route of eliminationExcretion is predominantly via the kidney in the unchanged form. Sotalol is excreted in the milk of laboratory animals and has been reported to be present in human milk.
Half lifeMean elimination half-life is 12 hours. Impaired renal function in geriatric patients can increase the terminal elimination half-life.
ClearanceNot Available
ToxicityThe most common signs to be expected are bradycardia, congestive heart failure, hypotension, bronchospasm and hypoglycemia. In cases of massive intentional overdosage (2-16 grams) of sotalol the following clinical findings were seen: hypotension, bradycardia, cardiac asystole, prolongation of QT interval, Torsade de Pointes, ventricular tachy-cardia, and premature ventricular complexes.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Sotalol Action PathwayDrug actionSMP00660
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Sotalol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Sotalol.Experimental, Illicit
AcebutololThe risk or severity of adverse effects can be increased when Sotalol is combined with Acebutolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Sotalol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Sotalol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Sotalol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Sotalol is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideSotalol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetovanilloneAcetovanillone may decrease the antihypertensive activities of Sotalol.Investigational
AcetylcholineThe risk or severity of adverse effects can be increased when Sotalol is combined with Acetylcholine.Approved
AcetyldigitoxinSotalol may increase the bradycardic activities of Acetyldigitoxin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Sotalol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Sotalol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Sotalol.Experimental, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Sotalol.Approved
AlfentanilAlfentanil may increase the bradycardic activities of Sotalol.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Sotalol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Sotalol is combined with Aliskiren.Approved, Investigational
Aluminum hydroxideThe serum concentration of Sotalol can be decreased when it is combined with Aluminum hydroxide.Approved
Aluminum phosphateThe serum concentration of Sotalol can be decreased when it is combined with Aluminum phosphate.Approved
AmantadineAmantadine may increase the QTc-prolonging activities of Sotalol.Approved
AmbenoniumAmbenonium may increase the bradycardic activities of Sotalol.Approved
Ambroxol acefyllinateSotalol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental
AmifostineThe risk or severity of adverse effects can be increased when Sotalol is combined with Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Sotalol is combined with Amiloride.Approved
AminophyllineSotalol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Sotalol.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Sotalol.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Sotalol.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Sotalol.Approved, Illicit
AmodiaquineThe metabolism of Sotalol can be decreased when combined with Amodiaquine.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Sotalol.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Sotalol is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Sotalol is combined with Amyl Nitrite.Approved
AnagrelideAnagrelide may increase the QTc-prolonging activities of Sotalol.Approved
AnisodamineAnisodamine may decrease the antihypertensive activities of Sotalol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Sotalol.Approved
AnvirzelSotalol may increase the bradycardic activities of Anvirzel.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Sotalol is combined with Apraclonidine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Sotalol.Approved, Investigational
ArbutamineSotalol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Sotalol is combined with Arecoline.Experimental
ArformoterolSotalol may decrease the bronchodilatory activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Sotalol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Sotalol is combined with Arotinolol.Approved
Arsenic trioxideSotalol may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherSotalol may increase the QTc-prolonging activities of Artemether.Approved
AsenapineSotalol may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirAtazanavir may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Sotalol.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Sotalol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Sotalol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Sotalol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Sotalol is combined with Azilsartan medoxomil.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Sotalol.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Sotalol.Approved, Investigational
BambuterolSotalol may decrease the bronchodilatory activities of Bambuterol.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Sotalol.Experimental
BarbitalBarbital may increase the hypotensive activities of Sotalol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Sotalol is combined with Barnidipine.Approved
BedaquilineBedaquiline may increase the QTc-prolonging activities of Sotalol.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Sotalol.Approved
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Sotalol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved, Illicit
BepridilThe risk or severity of adverse effects can be increased when Sotalol is combined with Bepridil.Approved, Withdrawn
BeractantSotalol may increase the bradycardic activities of Beractant.Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Sotalol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Sotalol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
Betulinic AcidBetulinic Acid may decrease the antihypertensive activities of Sotalol.Investigational
Bismuth SubcitrateThe serum concentration of Sotalol can be decreased when it is combined with Bismuth Subcitrate.Approved
BisoprololThe risk or severity of adverse effects can be increased when Sotalol is combined with Bisoprolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Sotalol.Investigational
BortezomibBortezomib may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Sotalol.Approved
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Sotalol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Sotalol.Investigational
BucindololSotalol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Sotalol is combined with Bumetanide.Approved
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Sotalol.Approved, Investigational
BuserelinBuserelin may increase the QTc-prolonging activities of Sotalol.Approved
CabergolineSotalol may increase the vasoconstricting activities of Cabergoline.Approved
Calcium carbonateThe serum concentration of Sotalol can be decreased when it is combined with Calcium carbonate.Approved
CalfactantSotalol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Sotalol is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Sotalol is combined with Candesartan.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Sotalol is combined with Carbachol.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Sotalol is combined with Carbetocin.Approved
CarprofenCarprofen may decrease the antihypertensive activities of Sotalol.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Sotalol is combined with Carteolol.Approved
CarvedilolSotalol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Sotalol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Sotalol.Approved, Investigational
CeliprololSotalol may decrease the bronchodilatory activities of Celiprolol.Approved, Investigational
CeritinibSotalol may increase the bradycardic activities of Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Sotalol is combined with Cevimeline.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Sotalol.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Sotalol is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Sotalol.Approved, Vet Approved
ChlorpropamideSotalol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Sotalol.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Sotalol is combined with Cilnidipine.Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
CisaprideSotalol may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the QTc-prolonging activities of Sotalol.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Sotalol.Approved
ClenbuterolSotalol may decrease the bronchodilatory activities of Clenbuterol.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Sotalol is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Sotalol is combined with Clofarabine.Approved, Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Sotalol.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Sotalol.Approved
ClozapineClozapine may increase the QTc-prolonging activities of Sotalol.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Sotalol is combined with Conivaptan.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Sotalol.Vet Approved
CrizotinibCrizotinib may increase the QTc-prolonging activities of Sotalol.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Sotalol.Investigational
D-LimoneneD-Limonene may decrease the antihypertensive activities of Sotalol.Investigational
DabrafenibDabrafenib may increase the QTc-prolonging activities of Sotalol.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Sotalol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Sotalol can be increased when it is combined with Dapoxetine.Investigational
DasatinibDasatinib may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Sotalol.Approved
DegarelixDegarelix may increase the QTc-prolonging activities of Sotalol.Approved
DemecariumDemecarium may increase the bradycardic activities of Sotalol.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Sotalol.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Sotalol.Approved
DeslanosideSotalol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Sotalol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved, Vet Approved
DichlorvosDichlorvos may increase the bradycardic activities of Sotalol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Sotalol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Sotalol is combined with Diclofenamide.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Sotalol.Approved
DigitoxinSotalol may increase the bradycardic activities of Digitoxin.Approved
DigoxinDigoxin may increase the bradycardic activities of Sotalol.Approved
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Sotalol.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Sotalol is combined with Dinutuximab.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Sotalol.Approved
DipivefrinSotalol may decrease the bronchodilatory activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Sotalol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Sotalol.Approved
DobutamineSotalol may decrease the bronchodilatory activities of Dobutamine.Approved
DofetilideDofetilide may increase the QTc-prolonging activities of Sotalol.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Sotalol.Approved
DomperidoneSotalol may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilDonepezil may increase the bradycardic activities of Sotalol.Approved
DoxazosinSotalol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Sotalol.Approved
DronedaroneDronedarone may increase the bradycardic activities of Sotalol.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Sotalol.Approved, Vet Approved
DroxicamDroxicam may decrease the antihypertensive activities of Sotalol.Approved
DroxidopaSotalol may decrease the bronchodilatory activities of Droxidopa.Approved, Investigational
DuloxetineSotalol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Sotalol.Investigational
DyphyllineSotalol may decrease the bronchodilatory activities of Dyphylline.Approved
E6201E6201 may decrease the antihypertensive activities of Sotalol.Investigational
EbselenEbselen may decrease the antihypertensive activities of Sotalol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Sotalol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Sotalol.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Sotalol is combined with Efonidipine.Approved
EliglustatSotalol may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Sotalol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Sotalol is combined with Enalaprilat.Approved
EphedraSotalol may decrease the bronchodilatory activities of Ephedra.Approved, Nutraceutical, Withdrawn
EPIBATIDINEThe risk or severity of adverse effects can be increased when Sotalol is combined with EPIBATIDINE.Experimental
EpinephrineSotalol may decrease the bronchodilatory activities of Epinephrine.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Sotalol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Sotalol is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Sotalol is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Sotalol is combined with Eprosartan.Approved
Ergoloid mesylateSotalol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineSotalol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
EribulinEribulin may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Sotalol.Approved, Vet Approved
EscitalopramSotalol may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Sotalol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Sotalol is combined with Etacrynic acid.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Sotalol.Approved, Investigational
EtodolacEtodolac may decrease the antihypertensive activities of Sotalol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Sotalol.Approved
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
EtoperidoneThe serum concentration of Sotalol can be increased when it is combined with Etoperidone.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Sotalol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Sotalol.Approved
exisulindexisulind may decrease the antihypertensive activities of Sotalol.Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Sotalol.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Sotalol.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Sotalol.Approved
FelodipineThe risk or severity of adverse effects can be increased when Sotalol is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Sotalol.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Sotalol is combined with Fenoldopam.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Sotalol.Approved
FenoterolSotalol may decrease the bronchodilatory activities of Fenoterol.Approved
FentanylFentanyl may increase the bradycardic activities of Sotalol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Sotalol.Vet Approved
FimasartanThe risk or severity of adverse effects can be increased when Sotalol is combined with Fimasartan.Approved
FingolimodSotalol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Sotalol.Approved, Withdrawn
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Sotalol.Approved, Withdrawn
FluconazoleFluconazole may increase the QTc-prolonging activities of Sotalol.Approved
FlunixinFlunixin may decrease the antihypertensive activities of Sotalol.Vet Approved
FluoxetineFluoxetine may increase the QTc-prolonging activities of Sotalol.Approved, Vet Approved
FlupentixolSotalol may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineFluphenazine may increase the hypotensive activities of Sotalol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Sotalol.Approved, Investigational
FormoterolSotalol may decrease the bronchodilatory activities of Formoterol.Approved, Investigational
FoscarnetFoscarnet may increase the QTc-prolonging activities of Sotalol.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Fosinopril.Approved
FurosemideThe risk or severity of adverse effects can be increased when Sotalol is combined with Furosemide.Approved, Vet Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Sotalol.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Sotalol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Sotalol.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Sotalol.Approved, Nutraceutical
GlibornurideSotalol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideSotalol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideSotalol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideSotalol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneSotalol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideSotalol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideSotalol may increase the hypoglycemic activities of Glyburide.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Sotalol.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
GTS-21The risk or severity of adverse effects can be increased when Sotalol is combined with GTS-21.Investigational
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved, Investigational
HaloperidolHaloperidol may increase the QTc-prolonging activities of Sotalol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Sotalol is combined with Halothane.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Sotalol.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Sotalol.Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Sotalol.Approved
HMPL-004HMPL-004 may decrease the antihypertensive activities of Sotalol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Sotalol.Investigational
HydralazineThe risk or severity of adverse effects can be increased when Sotalol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Sotalol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Sotalol is combined with Hydroflumethiazide.Approved
HydroxychloroquineThe metabolism of Sotalol can be decreased when combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Sotalol.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
IbuprofenIbuprofen may decrease the antihypertensive activities of Sotalol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Sotalol.Withdrawn
IbutilideIbutilide may increase the QTc-prolonging activities of Sotalol.Approved
IcatibantIcatibant may decrease the antihypertensive activities of Sotalol.Approved
IloperidoneSotalol may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Sotalol is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Imidapril.Investigational
ImipramineImipramine may increase the QTc-prolonging activities of Sotalol.Approved
IndacaterolSotalol may decrease the bronchodilatory activities of Indacaterol.Approved
IndalpineThe serum concentration of Sotalol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Sotalol.Approved
IndomethacinIndomethacin may decrease the antihypertensive activities of Sotalol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Sotalol.Withdrawn
IndoraminSotalol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkSotalol may increase the hypoglycemic activities of Insulin Pork.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Sotalol is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Sotalol is combined with Isocarboxazid.Approved
IsoetarineSotalol may decrease the bronchodilatory activities of Isoetarine.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Sotalol.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Sotalol.Approved, Withdrawn
IsoprenalineSotalol may decrease the bronchodilatory activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Sotalol is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Sotalol is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Sotalol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Sotalol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the QTc-prolonging activities of Sotalol.Approved
ItraconazoleItraconazole may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Sotalol.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Sotalol.Experimental
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Sotalol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Sotalol.Approved
LabetalolSotalol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Sotalol is combined with Lacidipine.Approved
LacosamideSotalol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LanreotideSotalol may increase the bradycardic activities of Lanreotide.Approved
LapatinibLapatinib may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Sotalol.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Sotalol.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Sotalol is combined with Lercanidipine.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Sotalol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Sotalol is combined with Levobupivacaine.Approved
LevodopaSotalol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
LevomilnacipranThe serum concentration of Sotalol can be increased when it is combined with Levomilnacipran.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Sotalol is combined with Levosimendan.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Sotalol.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Sotalol.Investigational
LithiumLithium may increase the QTc-prolonging activities of Sotalol.Approved
LobelineThe risk or severity of adverse effects can be increased when Sotalol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved, Investigational
LopinavirSotalol may increase the QTc-prolonging activities of Lopinavir.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Sotalol.Approved
LosartanThe risk or severity of adverse effects can be increased when Sotalol is combined with Losartan.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Sotalol.Approved
LucinactantSotalol may increase the bradycardic activities of Lucinactant.Approved
LumefantrineSotalol may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Sotalol.Approved, Investigational
MagaldrateThe serum concentration of Sotalol can be decreased when it is combined with Magaldrate.Withdrawn
Magnesium carbonateThe serum concentration of Sotalol can be decreased when it is combined with Magnesium carbonate.Approved
Magnesium hydroxideThe serum concentration of Sotalol can be decreased when it is combined with Magnesium hydroxide.Approved
Magnesium oxideThe serum concentration of Sotalol can be decreased when it is combined with Magnesium oxide.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Sotalol.Approved
Magnesium TrisilicateThe serum concentration of Sotalol can be decreased when it is combined with Magnesium Trisilicate.Approved
MalathionMalathion may increase the bradycardic activities of Sotalol.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Sotalol is combined with Mannitol.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Sotalol.Approved
MasoprocolMasoprocol may decrease the antihypertensive activities of Sotalol.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Sotalol is combined with Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Sotalol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Sotalol.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Sotalol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Sotalol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Sotalol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Sotalol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Sotalol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Sotalol.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Sotalol.Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Sotalol is combined with Methacholine.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Sotalol.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Sotalol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Sotalol is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Sotalol.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Sotalol.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sotalol.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Sotalol is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Sotalol.Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Sotalol.Approved
MetipranololThe risk or severity of adverse effects can be increased when Sotalol is combined with Metipranolol.Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Sotalol is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Sotalol.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Sotalol.Approved
MidodrineSotalol may increase the bradycardic activities of Midodrine.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
MilnacipranThe serum concentration of Sotalol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Sotalol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Sotalol.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Sotalol.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Sotalol.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Sotalol.Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Sotalol.Approved
MoricizineMoricizine may increase the hypotensive activities of Sotalol.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Sotalol is combined with Morphine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Sotalol is combined with Moxonidine.Approved
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Sotalol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Sotalol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Sotalol is combined with Nabilone.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Sotalol.Approved
NadololThe risk or severity of adverse effects can be increased when Sotalol is combined with Nadolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Sotalol.Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Sotalol.Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Sotalol.Approved, Vet Approved
NCX 4016NCX 4016 may decrease the antihypertensive activities of Sotalol.Investigational
NebivololThe risk or severity of adverse effects can be increased when Sotalol is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Sotalol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirNelfinavir may increase the QTc-prolonging activities of Sotalol.Approved
NeostigmineNeostigmine may increase the bradycardic activities of Sotalol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Sotalol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Sotalol is combined with Nesiritide.Approved, Investigational
NicardipineNicardipine may increase the QTc-prolonging activities of Sotalol.Approved
NicorandilNicorandil may increase the hypotensive activities of Sotalol.Approved
NicotineThe risk or severity of adverse effects can be increased when Sotalol is combined with Nicotine.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Sotalol is combined with Nicotine bitartrate.Approved
NifedipineNifedipine may increase the hypotensive activities of Sotalol.Approved
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Sotalol.Approved
NilotinibSotalol may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Sotalol is combined with Nilvadipine.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Sotalol.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Sotalol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Sotalol.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Sotalol is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Sotalol is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Sotalol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Sotalol is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Sotalol.Approved
NorepinephrineSotalol may decrease the bronchodilatory activities of Norepinephrine.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Sotalol.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Sotalol.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Sotalol is combined with Obinutuzumab.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Sotalol.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Sotalol.Approved, Investigational
OlodaterolSotalol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Sotalol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Sotalol.Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Sotalol.Approved
OrciprenalineSotalol may decrease the bronchodilatory activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Sotalol.Vet Approved
OuabainSotalol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Sotalol.Approved
OxprenololThe risk or severity of adverse effects can be increased when Sotalol is combined with Oxprenolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Sotalol.Withdrawn
OxytocinOxytocin may increase the QTc-prolonging activities of Sotalol.Approved, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Sotalol is combined with Paclitaxel.Approved, Vet Approved
PaliperidoneSotalol may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatPanobinostat may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Sotalol is combined with Papaverine.Approved
ParecoxibParecoxib may decrease the antihypertensive activities of Sotalol.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Sotalol.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Sotalol.Approved
PenbutololThe risk or severity of adverse effects can be increased when Sotalol is combined with Penbutolol.Approved, Investigational
PentamidinePentamidine may increase the QTc-prolonging activities of Sotalol.Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Sotalol.Approved, Vet Approved
PerazinePerazine may increase the hypotensive activities of Sotalol.Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Sotalol.Approved
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Perindopril.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Sotalol.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Sotalol is combined with Phenelzine.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Sotalol.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Sotalol is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Sotalol is combined with Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Sotalol.Approved, Vet Approved
PhenylpropanolamineSotalol may decrease the bronchodilatory activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Sotalol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Sotalol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Sotalol.Approved, Investigational
PimozideSotalol may increase the QTc-prolonging activities of Pimozide.Approved
PindololThe risk or severity of adverse effects can be increased when Sotalol is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Sotalol is combined with Pipamperone.Approved
PirbuterolSotalol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Sotalol.Investigational
PiroxicamPiroxicam may decrease the antihypertensive activities of Sotalol.Approved, Investigational
Poractant alfaSotalol may increase the bradycardic activities of Poractant alfa.Approved
PosaconazolePosaconazole may increase the QTc-prolonging activities of Sotalol.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Sotalol is combined with Pramipexole.Approved, Investigational
PrazosinSotalol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Sotalol.Approved
PrimidonePrimidone may increase the hypotensive activities of Sotalol.Approved, Vet Approved
ProcainamideSotalol may increase the QTc-prolonging activities of Procainamide.Approved
ProcaterolSotalol may decrease the bronchodilatory activities of Procaterol.Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Sotalol.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Sotalol.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Sotalol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Sotalol.Approved
PropafenoneThe serum concentration of Sotalol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Sotalol.Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Sotalol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Sotalol is combined with Propranolol.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Sotalol.Approved
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Sotalol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Sotalol.Approved
QuetiapineSotalol may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Quinapril.Approved, Investigational
QuinidineSotalol may increase the QTc-prolonging activities of Quinidine.Approved
QuinineQuinine may increase the QTc-prolonging activities of Sotalol.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Sotalol.Approved
RanolazineRanolazine may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Sotalol is combined with Rasagiline.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Sotalol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Sotalol is combined with Remifentanil.Approved
ReserpineReserpine may increase the hypotensive activities of Sotalol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Sotalol.Experimental, Investigational
RifampicinThe serum concentration of Sotalol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Sotalol can be decreased when it is combined with Rifapentine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Sotalol.Approved
RiociguatThe risk or severity of adverse effects can be increased when Sotalol is combined with Riociguat.Approved
RisperidoneSotalol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineSotalol may decrease the bronchodilatory activities of Ritodrine.Approved
RitonavirRitonavir may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
RivastigmineRivastigmine may increase the bradycardic activities of Sotalol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Sotalol.Investigational, Withdrawn
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Sotalol is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Sotalol is combined with Rotigotine.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Sotalol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sotalol is combined with Sacubitril.Approved
SalbutamolSotalol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Sotalol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Sotalol.Approved, Vet Approved
SalmeterolSotalol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Sotalol.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Sotalol.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Sotalol is combined with Selegiline.Approved, Investigational, Vet Approved
SeratrodastSeratrodast may decrease the antihypertensive activities of Sotalol.Approved, Investigational
SertralineSertraline may increase the QTc-prolonging activities of Sotalol.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Sotalol.Approved, Vet Approved
SilodosinSotalol may increase the orthostatic hypotensive activities of Silodosin.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Sotalol is combined with Sodium Nitrite.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Sotalol.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Sotalol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Sotalol.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Sotalol is combined with Streptokinase.Approved
SufentanilSotalol may increase the bradycardic activities of Sufentanil.Approved, Investigational
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Sotalol.Approved
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Sotalol.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Sotalol.Approved, Vet Approved
SulindacSulindac may decrease the antihypertensive activities of Sotalol.Approved
SunitinibSunitinib may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
SuprofenSuprofen may decrease the antihypertensive activities of Sotalol.Approved, Withdrawn
TacrineTacrine may increase the bradycardic activities of Sotalol.Withdrawn
TamoxifenTamoxifen may increase the QTc-prolonging activities of Sotalol.Approved
TamsulosinSotalol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TelavancinTelavancin may increase the QTc-prolonging activities of Sotalol.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Sotalol.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Sotalol is combined with Telmisartan.Approved, Investigational
TenoxicamTenoxicam may decrease the antihypertensive activities of Sotalol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Sotalol.Vet Approved
TerazosinSotalol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbutalineSotalol may decrease the bronchodilatory activities of Terbutaline.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Sotalol.Approved
TetrabenazineSotalol may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Sotalol is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineSotalol may decrease the bronchodilatory activities of Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Sotalol.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Sotalol.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Sotalol.Approved, Vet Approved
ThioridazineSotalol may increase the QTc-prolonging activities of Thioridazine.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Sotalol.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Sotalol.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Sotalol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Sotalol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Sotalol.Approved, Investigational
TolazamideSotalol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineThe risk or severity of adverse effects can be increased when Sotalol is combined with Tolazoline.Approved, Vet Approved
TolbutamideSotalol may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Sotalol is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Sotalol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Sotalol.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Sotalol.Approved
ToremifeneSotalol may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Sotalol is combined with Trandolapril.Approved
TranilastTranilast may decrease the antihypertensive activities of Sotalol.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Sotalol is combined with Tranylcypromine.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Sotalol is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Sotalol.Approved
TrichlorfonTrichlorfon may increase the bradycardic activities of Sotalol.Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Sotalol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Sotalol.Approved, Vet Approved
TrimazosinSotalol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Sotalol.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Sotalol.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Sotalol.Approved, Vet Approved
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Sotalol.Approved
TubocurarineTubocurarine may increase the bradycardic activities of Sotalol.Approved
ValdecoxibValdecoxib may decrease the antihypertensive activities of Sotalol.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Sotalol.Approved, Investigational
VandetanibSotalol may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Sotalol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Sotalol is combined with Varenicline.Approved, Investigational
VemurafenibSotalol may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Sotalol.Approved
VerapamilThe risk or severity of adverse effects can be increased when Sotalol is combined with Verapamil.Approved
VilanterolSotalol may decrease the bronchodilatory activities of Vilanterol.Approved
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Sotalol.Approved, Investigational
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Sotalol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Sotalol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Sotalol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Sotalol.Approved
ZomepiracZomepirac may decrease the antihypertensive activities of Sotalol.Withdrawn
ZuclopenthixolSotalol may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet. 1996 Jul 6;348(9019):7-12. [PubMed:8691967 ]
External Links
ATC CodesC07AA57C07BA07C07AA07
AHFS Codes
  • 24:24.00
PDB EntriesNot Available
FDA labelDownload (93.8 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.995
Blood Brain Barrier+0.9382
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.6708
P-glycoprotein inhibitor INon-inhibitor0.8881
P-glycoprotein inhibitor IINon-inhibitor0.9638
Renal organic cation transporterNon-inhibitor0.9514
CYP450 2C9 substrateNon-substrate0.7392
CYP450 2D6 substrateNon-substrate0.8296
CYP450 3A4 substrateNon-substrate0.6194
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8807
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8276
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.587
BiodegradationNot ready biodegradable0.9949
Rat acute toxicity2.2873 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.846
hERG inhibition (predictor II)Non-inhibitor0.8701
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Academic pharmaceuticals inc
  • Bayer healthcare pharmaceuticals inc
  • Upsher smith laboratories inc
  • Amneal pharmaceutical
  • Apotex inc
  • Apotex inc etobicoke site
  • Impax pharmaceuticals
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral160 mg
TabletOral80 mg
TabletOral240 mg
InjectionIntravenous15 mg/mL
TabletOral120 mg/1
TabletOral160 mg/1
TabletOral240 mg/1
TabletOral80 mg/1
SolutionOral5 mg/mL
Prices
Unit descriptionCostUnit
Betapace AF 100 160 mg tablet Box538.2USD box
Betapace AF 60 120 mg tablet Bottle311.06USD bottle
Betapace 240 mg tablet8.94USD tablet
Sotalol hcl 150 mg/10 ml vial7.8USD ml
Betapace 160 mg tablet6.87USD tablet
Betapace af 160 mg tablet6.24USD tablet
Sorine 240 mg tablet5.6USD tablet
Betapace 120 mg tablet5.5USD tablet
Sotalol HCl 240 mg tablet5.29USD tablet
Sotalol 240 mg tablet5.09USD tablet
Betapace af 120 mg tablet4.99USD tablet
Sotalol HCl (AF) 160 mg tablet4.45USD tablet
Sorine 160 mg tablet4.31USD tablet
Sotalol af 160 mg tablet4.27USD tablet
Betapace 80 mg tablet4.12USD tablet
Sotalol HCl 160 mg tablet4.07USD tablet
Sotalol 160 mg tablet3.92USD tablet
Betapace af 80 mg tablet3.74USD tablet
Sotalol HCl (AF) 120 mg tablet3.56USD tablet
Sorine 120 mg tablet3.46USD tablet
Sotalol af 120 mg tablet3.42USD tablet
Sotalol HCl 120 mg tablet3.26USD tablet
Sotalol 120 mg tablet3.13USD tablet
Sotalol HCl 80 mg tablet2.67USD tablet
Sotalol HCl (AF) 80 mg tablet2.67USD tablet
Sorine 80 mg tablet2.61USD tablet
Sotalol af 80 mg tablet2.56USD tablet
Sotalol 80 mg tablet2.35USD tablet
Apo-Sotalol 160 mg Tablet0.68USD tablet
Co Sotalol 160 mg Tablet0.68USD tablet
Mylan-Sotalol 160 mg Tablet0.68USD tablet
Novo-Sotalol 160 mg Tablet0.68USD tablet
Nu-Sotalol 160 mg Tablet0.68USD tablet
Pms-Sotalol 160 mg Tablet0.68USD tablet
Ratio-Sotalol 160 mg Tablet0.68USD tablet
Sandoz Sotalol 160 mg Tablet0.68USD tablet
Apo-Sotalol 80 mg Tablet0.62USD tablet
Co Sotalol 80 mg Tablet0.62USD tablet
Mylan-Sotalol 80 mg Tablet0.62USD tablet
Novo-Sotalol 80 mg Tablet0.62USD tablet
Nu-Sotalol 80 mg Tablet0.62USD tablet
Pms-Sotalol 80 mg Tablet0.62USD tablet
Ratio-Sotalol 80 mg Tablet0.62USD tablet
Sandoz Sotalol 80 mg Tablet0.62USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point206.5-207 °CPhysProp
water solubilitySoluble (5510 mg/L)Not Available
logP0.24BURGOT,G ET AL. (1990)
Predicted Properties
PropertyValueSource
Water Solubility0.782 mg/mLALOGPS
logP0.85ALOGPS
logP-0.4ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)10.07ChemAxon
pKa (Strongest Basic)9.43ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area78.43 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity71.12 m3·mol-1ChemAxon
Polarizability29.34 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as sulfanilides. These are organic aromatic compounds containing a sulfanilide moiety, with the general structure RS(=O)(=O)NC1=CC=CC=C1.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassSulfanilides
Direct ParentSulfanilides
Alternative Parents
Substituents
  • Sulfanilide
  • Aralkylamine
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Shimizu W, Antzelevitch C: Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. Circulation. 2000 Aug 8;102(6):706-12. [PubMed:10931813 ]
  2. Numaguchi H, Mullins FM, Johnson JP Jr, Johns DC, Po SS, Yang IC, Tomaselli GF, Balser JR: Probing the interaction between inactivation gating and Dd-sotalol block of HERG. Circ Res. 2000 Nov 24;87(11):1012-8. [PubMed:11090546 ]
  3. Wolpert C, Schimpf R, Giustetto C, Antzelevitch C, Cordeiro J, Dumaine R, Brugada R, Hong K, Bauersfeld U, Gaita F, Borggrefe M: Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. [PubMed:15673388 ]
  4. Wolpert C, Schimpf R, Veltmann C, Giustetto C, Gaita F, Borggrefe M: Clinical characteristics and treatment of short QT syndrome. Expert Rev Cardiovasc Ther. 2005 Jul;3(4):611-7. [PubMed:16076272 ]
  5. Fedida D, Orth PM, Hesketh JC, Ezrin AM: The role of late I and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers. J Cardiovasc Electrophysiol. 2006 May;17 Suppl 1:S71-S78. [PubMed:16686685 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Lowe MD, Lynham JA, Grace AA, Kaumann AJ: Comparison of the affinity of beta-blockers for two states of the beta 1-adrenoceptor in ferret ventricular myocardium. Br J Pharmacol. 2002 Jan;135(2):451-61. [PubMed:11815381 ]
  2. Joseph SS, Lynham JA, Colledge WH, Kaumann AJ: Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):525-32. Epub 2004 Apr 2. [PubMed:15060759 ]
  3. Yalcin I, Choucair-Jaafar N, Benbouzid M, Tessier LH, Muller A, Hein L, Freund-Mercier MJ, Barrot M: beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25. doi: 10.1002/ana.21542. [PubMed:19259968 ]
  4. Doggrell SA: The effects of (+/-)-, (+)-, and (-)-atenolol, sotalol, and amosulalol on the rat left atria and portal vein. Chirality. 1993;5(1):8-14. [PubMed:8095397 ]
  5. Juberg EN, Minneman KP, Abel PW: Beta 1- and beta 2-adrenoceptor binding and functional response in right and left atria of rat heart. Naunyn Schmiedebergs Arch Pharmacol. 1985 Sep;330(3):193-202. [PubMed:2865685 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Lowe MD, Lynham JA, Grace AA, Kaumann AJ: Comparison of the affinity of beta-blockers for two states of the beta 1-adrenoceptor in ferret ventricular myocardium. Br J Pharmacol. 2002 Jan;135(2):451-61. [PubMed:11815381 ]
  2. Joseph SS, Lynham JA, Colledge WH, Kaumann AJ: Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):525-32. Epub 2004 Apr 2. [PubMed:15060759 ]
  3. Yalcin I, Choucair-Jaafar N, Benbouzid M, Tessier LH, Muller A, Hein L, Freund-Mercier MJ, Barrot M: beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25. doi: 10.1002/ana.21542. [PubMed:19259968 ]
  4. Doggrell SA: The effects of (+/-)-, (+)-, and (-)-atenolol, sotalol, and amosulalol on the rat left atria and portal vein. Chirality. 1993;5(1):8-14. [PubMed:8095397 ]
  5. Juberg EN, Minneman KP, Abel PW: Beta 1- and beta 2-adrenoceptor binding and functional response in right and left atria of rat heart. Naunyn Schmiedebergs Arch Pharmacol. 1985 Sep;330(3):193-202. [PubMed:2865685 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23